Adicet Bio Obtains $51,000,000 Series A Funding

  • Feed Type
  • Date
    1/28/2016
  • Company Name
    Adicet Bio
  • Mailing Address
    Undisclosed Menlo Park, CA 94025 USA
  • Company Description
    Adicet Bio, Inc. is a biotechnology company engaged in the design and development of cutting-edge immunotherapies for cancer and other disease indications, with a focus on novel universal immune cell therapies (uICT).
  • Website
    Undisclosed
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $51,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    These significant financial resources will allow Adicet to progress its universal immune cell therapy (uICT) platform technology and related products and advance AIT’s programs and product pipeline.
  • M&A Terms
  • Venture Investor
    OrbiMed
  • Venture Investor
    Novartis Venture Fund
  • Venture Investor
    Pontifax Fund